<DOC>
	<DOCNO>NCT02732938</DOCNO>
	<brief_summary>The purpose Phase 1b/2 study evaluate safety tolerability PF-04136309 combination nab-paclitaxel gemcitabine , characterize dose-limiting toxicity ( DLTs ) overall safety profile escalate dose PF-04136309 associated schedule , determine maximum tolerate dose ( MTD ) , assess enhancement efficacy PF-04136309 combination nab-paclitaxel gemcitabine versus nab-paclitaxel + gemcitabine + placebo term Progression Free Survival .</brief_summary>
	<brief_title>Ph1b/2 Study PF-04136309 Combination With Gem/Nab-P First-line Metastatic Pancreatic Patients</brief_title>
	<detailed_description>The study 2 part : Phase 1b ( dose-finding cohort ) open label patient receive ascend dos PF-04136309 combination nab-paclitaxel + gemcitabine . The observation period dose-limiting toxicity ( DLTs ) Day 1 Day 28 . Pharmacokinetic ( PK ) pharmacodynamic ( PD ) property PF-04136309 also assess . The criterion dose escalation base modify toxicity probability interval ( mTPI ) method . After evaluate safety result ( eg , PK ) patient enrol dose escalation cohort , dose level select evaluate Recommended Phase 2 Dose ( RP2D ) . A minimum 6 patient , 12 patient , treat dose level establish RP2D . To evaluate safety pharmacodynamics , number patient enrol part study ( Phase 1b ) may N 20 . The study stop PF-04136309 dos explore appear overly toxic . Phase 2 randomize double blinded placebo control . Approximately 92 patient randomize 1:1 receive RP2D PF-04136309 combination nab-paclitaxel + gemcitabine ( ARM A ; n=46 ) versus nab-paclitaxel + gemcitabine + placebo ( ARM B ; n=46 ) . The primary objective enhancement efficacy term PFS . Patients treat long clinically benefit investigational product without unacceptable toxicity , objective disease progression , withdrawal consent .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Inclusion Criteria 1 . Histologically cytologically proven diagnosis metastatic ductal adenocarcinoma pancreas . 2 . All patient must provide baseline tumor sample registration . If archival sample available , patient must metastatic biopsy collect screen visit . 3 . Patient must receive previous radiotherapy , surgery , chemotherapy investigational therapy treatment metastatic disease . 4 . Measurable disease per RECIST v. 1.1 . 5 . Resolved acute effect prior therapy baseline severity Grade ≤1 NCI CTCAE . 6 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) 0 1 . 7 . Age ≥18 year . 8 . Adequate Bone Marrow , Renal liver Functions . Exclusion Criteria 1 . Patients know symptomatic brain metastasis require steroid . 2 . Prior therapy modulators monocyte TAM function . 3 . Participation study involve investigational drug ( ) ( Phases 14 ) within 4 week register current study and/or study participation . 4 . Diagnosis second malignancy within last 3 year , except adequately treat basal cell carcinoma , squamous cell skin carcinoma situ cervical carcinoma . 5 . Known hypersensitivity nabpaclitaxel gemcitabine excipients . 6 . Any one follow currently previous 6 month : myocardial infarction , severe/unstable angina , coronary/peripheral artery bypass graft , symptomatic congestive heart failure , cerebrovascular accident , transient ischemic attack ; symptomatic pulmonary embolism ; congenital long QT syndrome , torsades de point , arrhythmia ( include sustain ventricular tachyarrhythmia ventricular fibrillation ) , right bundle branch block leave anterior hemiblock ( bifascicular block ) , ongoing cardiac dysrhythmias NCI CTCAE Grade &gt; =2 , atrial fibrillation grade , QTc interval &gt; 470 msec screening . 7 . Concurrent administration herbal preparation . 8 . Use oral anticoagulant . Use subcutaneous anti coagulation allow . Concurrent use potent moderate inhibitor inducer CYP3A4 and/or CYP2C8 . 9 . Active clinically significant bacterial , fungal viral infection include hepatitis B ( HBV ) , hepatitis C ( HCV ) , know human immunodeficiency virus ( HIV ) acquire immunodeficiency syndrome ( AIDS ) relate illness . 10 . History interstitial lung disease , slowly progressive dyspnea unproductive cough , sarcoidosis , silicosis , idiopathic pulmonary fibrosis , pulmonary hypersensitivity pneumonitis multiple allergy . 11 . Other severe acute chronic medical psychiatric condition , include recent ( within past year ) active suicidal ideation behavior ) laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result , judgment Investigator , would make patient inappropriate entry study . 12 . Pregnant female patient ; breastfeed female patient ; male patient partner currently pregnant , male patient able father child female patient childbearing potential unwilling unable use two ( 2 ) highly effective method contraception outline protocol duration study 28 day last dose PF04136309 , 6 month last dose nabpaclitaxel , gemcitabine , . 13 . Patients investigational site staff member directly involved conduct trial family member , site staff member otherwise supervised Investigator , patient Pfizer employee directly involve conduct trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>CCR2i , nab-paclitaxel , Abraxane , gemcitabine , pancreas</keyword>
</DOC>